Lena Brundin
Laboratory

Overview

Behavioral Medicine

The laboratory of Dr. Lena Brundin investigates how inflammation in the periphery and central nervous systems contributes to neurological disorders, such as Parkinson’s disease, and psychiatric symptoms, such as depression, anxiety and suicidal thoughts/behavior.

Inflammation can be caused by many different factors and generates a cascade of cytokines, chemokines and metabolites that have intricate effects on neurons and other brain cells. The details of how inflammation impacts the central nervous system are just beginning to be understood. In our studies, we seek to identify inflammatory changes and link them to neurological symptoms. Through this approach, we aim to find novel therapeutic strategies that target inflammation and improve treatment outcomes.

Recent Tweets

Tweets by brundin_lena

Our Impact

We’re raising thousands to save millions.

We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.

118 papers published in 2022
48 papers in high-impact journals in 2022
42 clinical trials launched

Support VAI

Lena Brundin, M.D., Ph.D.

Professor, Department of Neurodegenerative Science

Areas of Expertise

Depression, suicide, inflammation, glutamate, perinatal depression, clinical studies, translational research

Biography

Dr. Lena Brundin earned her Ph.D. in neurobiology and her M.D. from Lund University, Sweden, where she specialized in clinical psychiatry and later attained the rank of associate professor. In 2012, she joined Van Andel Institute and Michigan State University College of Human Medicine in Grand Rapids, Mich. She is currently a professor in the Institute’s Department for Neurodegenerative Science.

Dr. Brundin’s research spans basic and clinical research, and focuses on the role of inflammatory mediators in psychiatric and neurological conditions, particularly the effects of the kynurenine metabolic pathway in depression and Parkinson’s disease. Her studies were among the first to indicate a role for inflammatory cytokines in suicidality, a finding that one day may help develop biomarkers for depression and suicide risk. She is currently the principal investigator on an R01-funded clinical trial that investigates the role of the kynurenine pathway in depressive patients with suicide risk. She also analyzes the potential of these metabolites as biomarkers and modulators of disease progression in Parkinson’s disease, funded by the Michael J. Fox Foundation. Further, she pursues studies aimed at identifying triggers of these disorders, such as bacterial, parasitic and viral infections.

Selected Publications

Sha Q, Madaj Z, Keaton S, Escobar Galvis ML, Smart L, Krzyzanowksi S, Fezleabas AT, Leach R, Postolache TT, Achtyes AD, Brundin L. 2022. Cytokines and trytophan metabolites can predict depressive symptoms in pregnancy. Transl Psych 12(35).

Kasen A, Houck C, Burmeister AR, Sha Q, Brundin L, Brundin P. 2022. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson’s disease. Neurobiol Dis 166:105654.

George S, Tyson T, Rey NL, Sheridan R, Peelaerts W, Becker K, Schulz E, Meyerdirk L, Burmeister AR, von Linstow CU, Steiner JA, Escobar Galvis ML, Ma J, Pospisilik JA, Labrie V, Brundin L, Brundin P. 2021. T cells limit accumulation of aggregate pathology following intrastratial injection of a-synuclein fibrils. J Park Dis. 11(2):585–603.

Bacelis J, Compagno M, George S, Pospisilik A, Brundin P, Torinsson A, Brundin L. 2021. Decreased risk of Parkinson’s disease after rheumatoid arthritis diagnosis: a nested case-control study with matched cases and controls. J Parkinson’s Dis.

Li P, Killinger BA, Ensink E, Beddows I, Yilmaz A, Lubben N, Lamp J, Schilthuis M, Vega IE, Woltjer R, Pospisilik JA, Brundin P, Brundin L, Graham SF, Labrie V. 2021. Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson’s disease. Metabolites 11(1):29.

Sha Q, Achtyes E, Nagalla M, Keaton A, Smart L, Leach R, Brundin L. 2021. Associations between estrogen and progesterone, the kynurenine pathway, and inflammation in the post-partum. J Affect Dis 281:9–12.

George S, Rey NL, Tyson T, Esquibel C, Meyerdirk L, Schulz E, Pierce S, Burmeister AR, Madaj Z, Steiner JA, Escobar Galvis ML, Brundin L, Brundin P. 2019. Microglia affect alpha-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease. Mol Neurodegener 14:34.

Achtyes E, Keaton SA, Smart L, Burmeister AR, Heilman PL, Krzyzanowski S, Nagalla M, Guillemin GJ, Escobar Galvis ML, Lim CK, Muzik M, Postolache TT, Leach R, Brundin L. 2019. Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression. Brain Behav Immun.

Keaton SA, Madaj ZB, Heilman P, Smart L, Grit J, Gibbons R, Postolache TT, Roaten K, Achtyes ED, Brundin L. 2019. An inflammatory profile linked to increased suicide risk. J Affect Disord 247:57 65.

Ohlsson L, Gustafsson A, Lavant E, Suneson K, Brundin L, Westin A, Ljunggren L, Lindqvist D. 2018. Leaky gut biomarkers in depression and suicidal behavior. Acta Psychiatrica Scandinavica.

Labrie V, Brundin L. 2018. Harbingers of mental illness—infections associated with an increased risk for neuropsychiatric illness in children. JAMA Psych.

Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. 2018. Triggers, facilitators and aggravators: Redefining Parkinson’s disease pathogenesis. Trends Neurosci.

Killinger BA*, Madaj Z*, Sikora JW, Rey N, Haas AJ, Vepa Y, Lindqvist D, Chen H, Thomas PM, Brundin P, Brundin L, Labrie V. 2018. The veriform appendix impacts the risk of developing Parkinson’s. Sci Transl Med 10(465):eaar5280.

Thirtamara-Rajamani K, Li P, Escobar Galvis ML, Labrie V, Brundin P, Brundin L. 2017. Is the enzyme ACMSD a novel therapeutic target in Parkinson’s disease?. J Parkinson Dis 7(4):577–587.

Brundin L, Sellgren CM, Lim CK, Grit J, Pålsson E, Landén M, Samuelsson M, Lundgren K, Brundin P, Fuchs D, Postolache TT, Traskman-Bendz L, Guillemin GJ, Erhardt S. 2016. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl Psychiatry 6:e865.

Coetzee SG, Pierce S, Brundin P, Brundin L, Hazelett DJ, Coetzee GA. In press. Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology. Sci Rep.

Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Träskman-Bendz L, Guillemin GJ, Brundin L. 2013. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38:743–752.

Janelidze S, Ventorp F, Erhardt S, Hansson O, Minthon L, Flax J, Samuelsson M, Träskman-Bendz L, Brundin L. 2013. Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology 38(6):853–862.

Suchankova P, Holm G, Träskman-Bendz L, Brundin L, Ekman A. 2013. The +1444C>T polymorphism in the CRP gene: a study on personality traits and suicidal behaviour. Psychiatr Genet 23(2):70-76.

Bay-Richter C, Hallberg L, Ventorp F, Janelidze S, Brundin L. 2012. Aldosterone synergizes with peripheral inflammation to induce brain IL-1β expression and depressive-like effects. Cytokine 60(3): 749–754.

Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. 2012. Non-motor symptoms in patients with Parkinson’s disease—correlations with inflammatory cytokines in serum. PLoS One 7(10): e47387.

Zhang Y, Träskman-Bendz L, Janelidze S, Langenberg P, Saleh A, Constantine N, Okusaga O, Bay-Richter C, Brundin L*, Postolache TT*. 2012. Toxoplasma gondii immunoglobulin G antibodies and nonfatal suicidal self-directed violence. J Clin Psychiatry 73(8): 1069–1076.
*Shared last authorship